Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent - PubMed (original) (raw)
Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent
K A Shirey et al. Mucosal Immunol. 2010 May.
Abstract
Severe respiratory syncytial virus (RSV)-induced bronchiolitis has been associated with a mixed "Th1" and "Th2" cytokine storm. We hypothesized that differentiation of "alternatively activated" macrophages (AA-M phi) would mediate the resolution of RSV-induced lung injury. RSV induced interleukin (IL)-4 and IL-13 by murine lung and peritoneal macrophages, IL-4R alpha/STAT6-dependent AA-M phi differentiation, and significantly enhanced inflammation in the lungs of IL-4R alpha(-/-) mice. Adoptive transfer of wildtype macrophages to IL-4R alpha(-/-) mice restored RSV-inducible AA-M phi phenotype and diminished lung pathology. RSV-infected Toll-like receptor (TLR)4(-/-) and interferon (IFN)-beta(-/-) macrophages and mice also failed to express AA-M phi markers, but exhibited sustained proinflammatory cytokine production (e.g., IL-12) in vitro and in vivo and epithelial damage in vivo. TLR4 signaling is required for peroxisome proliferator-activated receptor gamma expression, a DNA-binding protein that induces AA-M phi genes, whereas IFN-beta regulates IL-4, IL-13, IL-4R alpha, and IL-10 expression in response to RSV. RSV-infected cotton rats treated with a cyclooxygenase-2 inhibitor increased expression of lung AA-M phi. These data suggest new treatment strategies for RSV that promote AA-M phi differentiation.
Figures
Fig. 1. RSV infection induces differentiation of AA-Mϕ
(A) Highly purified WT BALB/c BAL macrophage cultures were treated with medium only or infected with RSV. Supernatants were collected at the indicated time points and analyzed for IL-4 and IL-13 by ELISA. (B) WT BALB/c BAL macrophages were treated with medium alone, rIL-4, or RSV. Gene expression was analyzed by real-time PCR. Data are means ± SEM from a single representative experiment (N = 4). (C) WT C57BL/6 mice were mock- or RSV-infected and lungs harvested 4 d p.i. Frozen lung sections were stained for nuclei (DAPI; blue), F4/80 (green), and arginase-1 (red), then viewed by confocal microscopy. Arrows are positioned identically on each panel within a treatment to provide a reference point. The arrowhead in panels f–j illustrates a rare cell that is positive for F4/80, but not for arginase-1.
Fig. 2. Failure to induce AA-Mϕ prolongs CA-Mϕ phenotype
(A) WT BALB/c and IL-4Rα−/− peritoneal macrophages were treated as in Fig. 1 and mRNA expression measured. Data are derived from a single representative experiment (N = 3). (B) WT and IL-4Rα−/− mice were mock- or RSV-infected. Mice were sacrificed 4 d p.i., and arginase-1 and IL-12 p40 mRNA measured in lungs by real-time PCR. (C) WT and IL-4Rα−/− mice were treated as in (B). Lung pathology was scored as described in Methods. Results are compiled from 3 independent experiments. (D) WT and IL-4Rα−/− mice were mock- or RSV-infected. Lungs were harvested 4 d p.i. Lung pathology was scored (N = 4; 4 mice/treatment). Images shown are at 100x.
Fig. 3. Adoptive transfer of WT macrophages reconstitutes AA-Mϕ phenotype in IL-4Rα−/− mice
(A) WT BALB/c and IL-4Rα−/− mice, along with IL-4Rα−/− mice that received either 1.5 × 107 WT (WT→IL-4Rα−/−) or IL-4Rα−/− (IL-4Rα−/−→IL-4Rα−/−) macrophages i.p., were mock- or RSV-infected 5 d post-transfer. Lungs were harvested 4 d p.i. and analyzed for gene expression by real-time PCR. (B) Lung sections from mice in (A) were H&E stained and scored for lung pathology. Data represent one of 2 separate experiments with similar outcomes (10 mice/treatment).
Fig. 4. Differentiation of AA-Mϕ by RSV is TLR4-dependent
(A) WT C57BL/6 and TLR4−/− peritoneal macrophages were treated as indicated in Fig. 1 and analyzed for mRNA gene expression by real-time PCR (N = 3). (B) WT and TLR4−/− macrophages were treated as in (A) and analyzed for PPARγ mRNA gene expression by real-time PCR. (C) WT and TLR4−/− mice were mock- or RSV-infected. Lungs were harvested 4 d p.i. Lung pathology was scored (N = 4; 4 mice/treatment). Images shown are at 200x.
Fig. 5. RSV-induced AA-Mϕ and IL-10 production are IFN-β-dependent
(A) WT and IFN-β−/− peritoneal macrophages were treated as indicated and analyzed for mRNA by real-time PCR (N = 2). (B) WT or IFN-β−/− mice were mock- or RSV-infected. At 4 d p.i., mice were sacrificed and lungs analyzed for arginase-1, FIZZ1, and MR mRNA. (C) IL-10 and COX-2 mRNA were measured in the lungs of RSV-infected mice (see legend to (B)). (C) Mice were infected as in (B) and lungs fixed and stained with H&E 4 d p.i. (N = 4; 4 mice/treatment). Images shown are at 400x.
Fig. 6. Rapid activation of AA-Mϕ in cotton rats during re-infection and in response to COX-2 inhibition
(A) Cotton rats (4/group) were administered saline or infected with RSV. Animals were then RSV-infected 60 d after initial treatment. Lungs were harvested, total RNA isolated, and analyzed for IL-4, IL-13, and arginase-1 mRNA by RT-PCR and Southern blotting. (B) Cotton rats were mock- or RSV-infected. Infected rats were treated on day 3 p.i. with vehicle (saline) or paracoxib (100 mg/kg) i.p. All animals were sacrificed 4 d p.i. and lung samples evaluated for mRNA expression for the indicated genes. Each lane represents RNA from one cotton rat and results are representative of 3 separate experiments.
Fig. 7. Hypothetical model for the role of AA-Mϕ during RSV infection
Similar articles
- Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.
Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Gioannini TL, Weiss JP, Chow JC, Hawkins LD, Vogel SN, Blanco JC. Rallabhandi P, et al. mBio. 2012 Aug 7;3(4):e00218-12. doi: 10.1128/mBio.00218-12. Print 2012. mBio. 2012. PMID: 22872782 Free PMC article. - Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms.
Senft AP, Taylor RH, Lei W, Campbell SA, Tipper JL, Martinez MJ, Witt TL, Clay CC, Harrod KS. Senft AP, et al. Am J Respir Cell Mol Biol. 2010 Apr;42(4):404-14. doi: 10.1165/rcmb.2008-0229OC. Epub 2009 Jun 5. Am J Respir Cell Mol Biol. 2010. PMID: 19502390 Free PMC article. - Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
Shirey KA, Lai W, Pletneva LM, Karp CL, Divanovic S, Blanco JC, Vogel SN. Shirey KA, et al. Mucosal Immunol. 2014 May;7(3):549-57. doi: 10.1038/mi.2013.71. Epub 2013 Sep 25. Mucosal Immunol. 2014. PMID: 24064666 Free PMC article. - Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity.
Wronski S, Dannenmaier J, Schild S, Macke O, Müller L, Burmeister Y, Seilheimer B, Müller M. Wronski S, et al. PLoS One. 2018 Apr 19;13(4):e0195822. doi: 10.1371/journal.pone.0195822. eCollection 2018. PLoS One. 2018. PMID: 29672626 Free PMC article.
Cited by
- Diverging patterns in innate immunity against respiratory viruses during a lifetime: lessons from the young and the old.
Smits HH, Jochems SP. Smits HH, et al. Eur Respir Rev. 2024 Jun 12;33(172):230266. doi: 10.1183/16000617.0266-2023. Print 2024 Apr. Eur Respir Rev. 2024. PMID: 39009407 Free PMC article. Review. - Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis-A Potential Therapeutic Intervention to Improve Lung Health.
Verma A, Bhagchandani T, Rai A, Nikita, Sardarni UK, Bhavesh NS, Gulati S, Malik R, Tandon R. Verma A, et al. ACS Omega. 2024 Mar 19;9(13):14648-14671. doi: 10.1021/acsomega.3c05846. eCollection 2024 Apr 2. ACS Omega. 2024. PMID: 38585101 Free PMC article. Review. - Immunomodulation of periodontitis with SPMs.
Sahni V, Van Dyke TE. Sahni V, et al. Front Oral Health. 2023 Oct 20;4:1288722. doi: 10.3389/froh.2023.1288722. eCollection 2023. Front Oral Health. 2023. PMID: 37927821 Free PMC article. Review. - Host Responses to Respiratory Syncytial Virus Infection.
Agac A, Kolbe SM, Ludlow M, Osterhaus ADME, Meineke R, Rimmelzwaan GF. Agac A, et al. Viruses. 2023 Sep 26;15(10):1999. doi: 10.3390/v15101999. Viruses. 2023. PMID: 37896776 Free PMC article. Review. - Macrophages Orchestrate Airway Inflammation, Remodeling, and Resolution in Asthma.
Britt RD Jr, Ruwanpathirana A, Ford ML, Lewis BW. Britt RD Jr, et al. Int J Mol Sci. 2023 Jun 21;24(13):10451. doi: 10.3390/ijms241310451. Int J Mol Sci. 2023. PMID: 37445635 Free PMC article. Review.
References
- Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J. Pediatr. 2003;143:S112–S117. - PubMed
- Blanco JCG, Boukhvalova M, Pletneva L, Prince GA, Vogel SN. Rethinking respiratory syncytial virus vaccines. Recent Res. Devel. Experimental Med. 2004;1:75–94. Appendix 1.
- Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2006;24:5027–5035. - PubMed
- Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. Interferon-inducible Mx gene expression in cotton rats: cloning, characterization, and expression during influenza viral infection. J. Interferon Cytokine Res. 2006;26:914–921. - PubMed
- Kurt-Jones EA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 2000;1:398–401. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI059775-05/AI/NIAID NIH HHS/United States
- R01 AI038985-15/AI/NIAID NIH HHS/United States
- R01 AI038985/AI/NIAID NIH HHS/United States
- R01 AI059775-04/AI/NIAID NIH HHS/United States
- R37 AI018797-26/AI/NIAID NIH HHS/United States
- AI-18797/AI/NIAID NIH HHS/United States
- AI59775/AI/NIAID NIH HHS/United States
- R37 AI018797/AI/NIAID NIH HHS/United States
- R37 AI018797-27/AI/NIAID NIH HHS/United States
- R29 AI038985/AI/NIAID NIH HHS/United States
- R01 AI018797/AI/NIAID NIH HHS/United States
- R01 AI057575/AI/NIAID NIH HHS/United States
- R56 AI018797/AI/NIAID NIH HHS/United States
- R01 AI038985-12A1/AI/NIAID NIH HHS/United States
- R01 AI038985-11/AI/NIAID NIH HHS/United States
- AI-057575/AI/NIAID NIH HHS/United States
- AI-38985/AI/NIAID NIH HHS/United States
- R01 AI057575-05/AI/NIAID NIH HHS/United States
- R01 AI057575-06A2/AI/NIAID NIH HHS/United States
- R01 AI059775/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous